CPR Invest - Silver Age - R EUR - Acc ISIN : LU1653750338

CPR Invest - Silver Age - R EUR - Acc
R(C) - LU1653750338
Asset class: Equities

YTD
As of 17/11/2026
7.67%

Risk IndicatorThe level of risk of the fund mainly reflects the risk of the market in which the fund is invested and, as the case may be, the leveraging strategy or inverse performance of the index. The capital initially invested does not benefit from any guarantee. The current level of risk does not indicate the future level of risk and may change over time. The lowest risk level is not equal to a risk-free investment.
1234567
Lower Risk
Higher Risk
The risk indicator assumes you keep the product according to the holding period.

NAV
As of 18/11/2026
€155.37

SFDR ClassificationSustainable Finance Disclosure Regulation
Art. 8

Fund AUM
As of 18/11/2026
€117.53M
The fund's investment objective is to outperform the European equity markets over the long-term (minimum five years) by capitalising on the growth of European stocks related to the ageing of the population.

NAVs

NAV from 20/09/2017 to 18/11/2026
Select period
Created with Highcharts 11.4.8CPR Invest - Silver Age - R EUR - AccJan '18Jul '18Jan '19Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '266080100120140160180

Performance

Change in NAV in base 100
FundCPR Invest - Silver Age - R EUR - Acc (56.89% over the period)
Select period
Created with Highcharts 11.4.8CPR Invest - Silver Age - R EUR - AccBenchmarkJan '18Jul '18Jan '19Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '265075100125150175200225250
FundCPR Invest - Silver Age - R EUR - Acc (56.89% over the period)
Select period
Created with Highcharts 11.4.8CPR Invest - Silver Age - R EUR - AccBenchmarkJan '18Jul '18Jan '19Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '265075100125150175200225250

Portfolio Analysis

Repartition 10/31/2026
Created with Highcharts 11.4.8Values22.75​22.7522.59​22.5911.29​11.2910.33​10.339.51​9.516.61​6.613.50​3.501.51​1.511.29​1.29Portfolio024681012141618202224PharmaceuticalsAsset GatherersRoboticsUnknownLeisuresHealth Care EquipmentHPCDependencySecurityHighcharts.com

Management commentary

Effective date: 31/10/2026Market Update
European markets rose by +1.9% in October, with the STOXX 600 at 646.75 points, bringing its YTD performance to 9.2%. The start of the month remained mainly driven by macroeconomic factors, including tensions in bond markets, geopolitical uncertainties, and oil price fluctuations. The start of the Q3 earnings season gradually shifted the market’s focus back to microeconomics (Q3 STOXX 600 EPS growth expected at +22% yoy, according to Bloomberg forecasts). This support allowed European equities to advance, but was not enough to dispel sovereign concerns, particularly pronounced in France. Political, social, and budgetary uncertainties pushed the 10-year OAT up to 5.15%, its highest level since 2002, and the OAT-Bund spread to 175 bps on October 22, the highest since 2011. The French yield even briefly exceeded that of the US Treasury, before returning to 4.94% (+11.5 bps for the month) after Moody’s maintained its Aa3 rating on the 23rd and Fitch its A+ rating on October 30 (although the outlook was downgraded). Oil also ended the month sharply higher, with Brent at $117.64 (+13.6%) and WTI at $104.12 (+15.2%), despite the gradual recovery of flows through Hormuz. The increase in attacks on ships and Saudi infrastructure, as well as the risk of new US-Israeli strikes against Iran after the midterm elections, have significantly increased the geopolitical risk premium.
 
On the macroeconomic front, October confirmed the resilience of global activity despite persistent inflationary pressures, placing central banks in an increasingly delicate balancing act. In the eurozone, GDP grew by +0.4% q/q in Q3, versus +0.2% expected, while the flash PMI fell to 51.9 in October, after 53.1 in September, but remained in expansion territory at the start of Q4. This resilience, however, masks divergent trajectories: Germany saw its inflation slow to +2.8% year-on-year in October, versus +3.0% expected and +3.3% in September, and recorded growth of +0.2% q/q, slightly above expectations, while France contracted by -0.1% q/q in Q3 and saw its national inflation accelerate to +3.4% year-on-year. In this context, the ECB kept its deposit rate at 2.50%, with the energy shock simultaneously increasing risks to both prices and growth, without yet significantly spreading to wages and core inflation. In the UK, activity also accelerated, with a composite PMI at 53.1, but inflation rose to +3.5%, reinforcing the prospect of a BoE rate hike in November. The US remains significantly more dynamic, with annualized growth of +3.4% in Q3, versus +2.2% in Q2, a composite PMI at 57.6, and jobless claims still low at 194k. Inflationary pressures remain persistent: headline PCE accelerated to +3.6% year-on-year in September, and core PCE to +3.1%, despite a slowdown in Q3 to +2.1% and +2.5% annualized, respectively. The Fed thus kept its rates at 3.75%-4.00%, but maintained a hawkish tone, leaving the door open for another hike.
 
At the sector level, healthcare (+14.1%) led by a wide margin, driven by UCB (+37.2%) and Financière de Tubize (+32.5%), which holds 36.3% of the laboratory. Boosted by Bimzelx in the US and Cimzia, UCB raised its 2026 targets for the second time, now expecting revenue growth of around 20% and adjusted EBITDA growth of +40% to +45% at constant exchange rates. Food and tobacco (+13.1%) benefited from solid earnings releases, with Imperial Brands (+20.2%) confirming its annual targets and announcing a new £1.5bn share buyback program, and Heineken (+16.1%), whose volumes rose by +4.8% in Q3 and net revenues by +4.6%, driven by double-digit growth in premium brands. Finally, energy (+8.7%) benefited from the nearly +13.6% rise in Brent, amid ongoing disruptions to Middle Eastern flows and escalating risks around Iran.
 
Conversely, banks (-10.6%) lagged behind, penalized by rising sovereign yields and widening spreads, which depreciated their bond portfolios and weighed particularly on Banco Santander (-17.9%), while NatWest (-15.8%) suffered from a flat net interest margin expected in 2027, against further growth anticipated by the market, as well as a 22% increase in provisions in Q3. Commodities (-8.5%) fell due to the drop in iron ore prices, amid fragile Chinese demand, but also company-specific factors, with lower gold and silver production at Fresnillo (-18.1%) and higher aluminum production costs at Norsk Hydro (-20.0%), while Rio Tinto (-14.2%) suffered from weak prices despite solid volumes.
 
Among stocks, Genmab (+67.0%) posted the best performance in the STOXX 600 after two major clinical successes: petosemtamab combined with pembrolizumab reduced the risk of death by 50% compared to pembrolizumab alone in head and neck cancer, and Rina-S reduced the risk of death by 57% in ovarian cancer. Wolters Kluwer (+28.5%) benefited from the launch of its first tax AI agents, capable of automatically preparing returns, realizing the monetization of AI in its professional software, as well as its share buyback program. Finally, EssilorLuxottica (+26.6%) benefited from a stronger-than-expected underlying Q3, with revenue of €7.49bn, up +7.2% at constant exchange rates, about 100 bps above consensus. The release was notably driven by the strength of legacy activities, with +10.6% growth in Direct-to-Consumer.
 
Portfolio Movements and Performance Analysis
Over the period from September 30 to October 30, 2026, the MSCI Europe rose by 2.15%. European equities evolved in an environment marked by rising energy prices linked to Middle East tensions, with Brent exceeding $110 per barrel, and high sovereign yields. French budget risk also weighed on domestic assets, while the OAT-Bund spread reached 170 bps. At the same time, stocks linked to artificial intelligence and semiconductors underwent unwinding, amid questions about monetization and investment financing. At the end of the period, the Fed and ECB maintained their rates, while eurozone GDP grew by 0.4% in the third quarter.
 
CPR Silver Age outperformed the MSCI Europe by +211 bps, with a gross performance of +4.26% versus +2.15% for the benchmark. Allocation contributed +266 bps, while selection weighed in at –51 bps. The absence of investment outside the investment universe contributed +129 bps. The main positive contributions came from the absence of investment in semiconductors – unwinding of the AI trade – ASML (+69 bps) and in banking, stressed by rate hikes and slowdown risks, HSBC (+37 bps) and Banco Santander (+28 bps).
 
Within the investment universe:
 
Pharmaceuticals were the top contributor, at +220 bps, including +191 bps from allocation and +30 bps from selection. Roche (+49 bps) rose by 19.3% amid quarterly revenue growth of 7% at constant exchange rates and confirmation of annual targets. Genmab (+44 bps) gained 67.0% after the publication of very positively received phase III results for Rina-S.
 
Healthcare Equipment added +23 bps, with +45 bps from allocation and –21 bps from selection. Air Liquide (+10 bps) rose by 5.9% after 3.0% organic quarterly growth and the announcement of a €1bn share buyback. Demant and EssilorLuxottica each contributed +6 bps; Demant gained 17.9% amid Oticon Zeal market share gains, while EssilorLuxottica rose by 26.6% after quarterly sales exceeded expectations.
 
Conversely, Robotics weighed in at –132 bps, including –115 bps from allocation and –18 bps from selection. Schneider Electric (–79 bps) fell by 18.7% in a context marked by the acquisition of PTC and its financing through a €6bn capital increase. ABB (–23 bps) declined by 8.1% despite solid orders, as the market reacted negatively to weaker growth in other activities.
 
Finally, Asset Managers weighed in at –64 bps, with +10 bps from allocation and –74 bps from selection. ING (–41 bps) fell by 10.3% after net profit came in 6% below consensus, despite a solid capital ratio.
 
Portfolio Movements
At the end of the period, we made adjustments by reducing our positions in private banks (Mediolanum, Banca Generali) and retirement insurers (ASR, ING) as well as in the best-performing pharmaceutical laboratories (Genmab, ArgenX, Sandoz, Galderma) to reposition ourselves in the robotics sector, which had fallen sharply (Schneider, ABB).
 
Risk Profile
The fund’s beta rose to 0.99, while tracking error decreased slightly to 5.22%. The breakdown of TE changed slightly compared to the previous month. The share of selection risk decreased to 30% of total active risk. Sector risk increased further, to 58%. The remainder, about 12%, is attributable to other components, notably currency risk (2%) and style risk (7%).
 
Thematic Outlook
In November, market direction should notably depend on the outcome of the US midterm elections on November 3, oil price trends, and monetary policy expectations. Historically, US markets have often risen after midterm elections, but this scenario remains conditional on energy price stabilization. A further escalation in the Middle East and a Brent price sustainably above $120 would, on the contrary, pose a risk to all equity markets. The Fed and ECB kept their rates unchanged in October, but markets still anticipate a hike in December in the face of persistent inflation.
 
In this context, the Silver Age strategy could continue to benefit from its exposure to defensive sectors and healthcare if investors remain focused on balance sheet quality, earnings visibility, and cash generation. Pharmaceuticals also have their own catalysts, linked to earnings releases and clinical advances, even if October’s strong contribution cannot be extrapolated. Conversely, an easing of yields and oil, accompanied by a return of risk appetite after the US elections, could favor a rebound in industrials, electrification, and robotics. Such a move could reduce the relative cost observed in October for this theme, provided that concerns about AI investment financing subside. The asset manager segment would remain more directly exposed to market trends, inflows, and financial conditions.
 
The relative profile of CPR Silver Age in November will therefore depend on the balance between, on the one hand, the continuation of the defensive rotation favoring healthcare and, on the other, a possible return to cyclical and technology sectors. Finally, the positive contribution from stocks absent from the universe cannot be considered sustainable: it could shrink or even reverse in the event of a rebound in banks, energy, or large European technology stocks. Diversification between healthcare, aging-related consumption, financial services, and automation will thus remain key to the strategy’s relative performance.

Characteristics

General data

Inception date
18/09/2017
First Nav Date
20/09/2017
Currency
EUR
Show more
Valuation
Daily
Minimum initial investment
1 10/1000° share(s)/equity
Minimum additional investment
1 10/1000° share(s)/equity

Costs Composition

One-off costs upon entry or exit (Investment EUR 10,000)If you exit after 1 year
Entry costsThis includes distribution costs of 5.00% of amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge.Up to €500.00
Exit costsWe do not charge an exit fee for this product, but the person selling you the product may do so.€0.00
Ongoing costs taken each year (Investment EUR 10,000)
Management fees and other administrative or operating costs1.50% of the value of your investment per year. This percentage is based on actual costs over the last year.€142.50
Transaction costsWe do not charge a transaction fee for this product€0.00
Incidental costs taken under specific conditions (Investment EUR 10,000)
Performance fees

15.00% annual outperformance of the reference asset 100% MSCI EUROPE NR Close + 1%. The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee.The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.

The performance fee is paid even if the performance of the share over the performance observation period is negative, while remaining higher than the performance of the Reference Asset.

€0.00

Codification

ISIN code
LU1653750338
Bloomberg code
Reuters code
LP68443632

Investment Objective

The fund's investment objective is to outperform the European equity markets over the long-term (minimum five years) by capitalising on the growth of European stocks related to the ageing of the population.

Documents

LanguageDocumentsTypeClosing Date
DE
PDF
01/09/2026
EN
PDF
01/09/2026
FR
PDF
01/09/2026
PDF
31/07/2024
PDF
16/04/2026
PDF
31/01/2026
IT
PDF
01/09/2026
FR
PDF
26/10/2016
Prices expressed in a currency other than the base currency of the portfolio are available for information purposes only. 
Nothing contained in this site constitutes a solicitation or offer by any member of CPR Asset Management to provide any investment advice or service or to purchase or sell any financial instruments. The information it contains aims to inform the subscriber by providing information on the UCITS supplemental to that appearing in the Information Memorandum. The material provided on this site is presented as of the date shown and "as is". CPR Asset Management does not expressly or impliedly warrant the accuracy of the information provided on this site and expressly disclaims any warranties of fitness of this site for any particular purpose. This material reflects the opinion of the management company at the date of printing. The material is based upon information that we consider reliable, but we do not represent it is accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any subscription should be based solely on the Information Memorandum provided to subscribers prior to the subscription and/or available upon request.The Key Informations document (KID) and the prospectus of the fund, as well as the annual and semi-annual reports are available free of charge on the website www.cpram.com and from the Representative or Paying Agents : UniCredit Bank Czech Republic and Slovakia, a.s., Bratislava, Šancová 1/A, Postal Code 813 33, Slovak Republic